Overview

A Pilot Efficacy and Safety Study of ST101 in Essential Tremor

Status:
Completed
Trial end date:
2011-12-01
Target enrollment:
Participant gender:
Summary
This study will look at the ability of ST101 to treat symptoms in subjects with Essential Tremor. This study will also examine the safety and tolerability of the drug. This study is evaluating one dose level of ST101 versus placebo in a cross-over fashion. This means that all patients will receive both ST101 and placebo, but they will receive it in a random (by chance) order.
Phase:
Phase 2
Details
Lead Sponsor:
Sonexa Therapeutics, Inc.